9,803 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by American Century Companies Inc.

American Century Companies Inc. acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the second quarter, HoldingsChannel.com reports. The institutional investor acquired 9,803 shares of the company’s stock, valued at approximately $201,000.

A number of other large investors have also modified their holdings of SNDX. BVF Inc. IL acquired a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth about $40,519,000. Avoro Capital Advisors LLC increased its stake in Syndax Pharmaceuticals by 65.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,222,222 shares of the company’s stock valued at $91,242,000 after buying an additional 1,666,667 shares during the period. Kynam Capital Management LP increased its stake in Syndax Pharmaceuticals by 41.5% during the 4th quarter. Kynam Capital Management LP now owns 5,660,000 shares of the company’s stock valued at $122,313,000 after buying an additional 1,660,000 shares during the period. Avidity Partners Management LP increased its stake in Syndax Pharmaceuticals by 40.0% during the 4th quarter. Avidity Partners Management LP now owns 3,950,000 shares of the company’s stock valued at $85,360,000 after buying an additional 1,129,000 shares during the period. Finally, Iron Triangle Partners LP acquired a new position in Syndax Pharmaceuticals during the 1st quarter valued at about $23,159,000.

Wall Street Analyst Weigh In

SNDX has been the topic of several research analyst reports. Scotiabank cut shares of Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 14th. Citigroup raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. lowered their target price on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus raised their target price on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 26th. Finally, Jefferies Financial Group initiated coverage on shares of Syndax Pharmaceuticals in a research note on Friday, June 28th. They set a “buy” rating and a $37.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.30.

Syndax Pharmaceuticals Trading Up 0.7 %

NASDAQ:SNDX opened at $18.82 on Friday. Syndax Pharmaceuticals, Inc. has a twelve month low of $11.22 and a twelve month high of $25.34. The company has a 50-day moving average of $19.69 and a 200-day moving average of $20.85. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -5.84 and a beta of 0.91.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.11. The business had revenue of $3.50 million for the quarter. During the same period last year, the business posted ($0.64) EPS. The company’s quarterly revenue was up 3499999990.0% on a year-over-year basis. On average, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.66 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).